Lista de obras - Carmen Tur - Dominio Público Uruguay

A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis

scientific article published on 10 May 2019

Acute disseminated encephalomyelitis: study of factors involved in a possible development towards multiple sclerosis

artículo científico publicado en 2008

An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.

artículo científico publicado en 2011

Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting

artículo científico publicado en 2018

Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease.

artículo científico publicado en 2017

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

artículo científico publicado en 2017

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

artículo científico publicado en 2014

CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: No.

artículo científico publicado en 2013

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

article

Clinical relevance of cortical network dynamics in early primary progressive MS

scientific article published on 25 February 2019

Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al

scientific article published on 27 January 2014

Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody

scientific article published on 06 February 2015

Commentary on Pique et al.'s paper entitled: Peripheral late reactivation of a previously typical monofocal Balo's concentric sclerosis lesion.

artículo científico publicado en 2015

Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS

scientific article published on 25 October 2010

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis

artículo científico publicado en 2016

Deep grey matter volume loss drives disability worsening in multiple sclerosis.

artículo científico publicado en 2018

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

artículo científico publicado en 2015

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

artículo científico publicado en 2017

Disrupted principal network organisation in multiple sclerosis relates to disability

artículo científico publicado en 2020

Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?

artículo científico publicado en 2009

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

artículo científico

Early accurate diagnosis crucial in multiple sclerosis

artículo científico

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

artículo científico publicado en 2013

Erratum: Author Correction: High-dimensional detection of imaging response to treatment in multiple sclerosis

artículo científico publicado en 2019

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

article

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients

artículo científico publicado en 2015

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

artículo científico publicado en 2015

Fatigue Management in Multiple Sclerosis

artículo científico publicado en 2016

Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis

artículo científico publicado en 2015

Fármacos modificadores de la enfermedad en la esclerosis múltiple y embarazo

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

artículo científico publicado en 2016

Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis.

artículo científico publicado en 2011

HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis

artículo científico publicado en 2016

HLA-DRB1*15 influences the development of brain tissue damage in early PPMS

artículo científico publicado en 2014

Has the time come to revisit our standard measures of disability progression in MS?

scientific article published on 26 October 2020

Head-to-head drug comparisons in multiple sclerosis: Urgent action needed

artículo científico publicado en 2019

Hemichorea-hemiballism secondary to infarction in the primary motor area: an atypical form of presentation of Moya moya syndrome

artículo científico publicado el 1 de mayo de 2011

High-dimensional detection of imaging response to treatment in multiple sclerosis

scientific article published on 10 June 2019

Ibudilast: a paradigm shift for progressive MS?

scientific article published on 02 December 2020

Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis

scientific article published on 17 August 2018

Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.

artículo científico publicado en 2011

Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis.

artículo científico publicado en 2016

Multiple sclerosis risk perception and acceptance for Brazilian patients

artículo científico publicado en 2018

NMO spectrum disorders: how wide is the spectrum?

artículo científico publicado en 2014

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision

artículo científico publicado en 2012

Natalizumab: risk stratification of individual patients with multiple sclerosis

artículo científico publicado en 2014

Neurite dispersion: a new marker of multiple sclerosis spinal cord pathology?

artículo científico publicado en 2017

Neurofilament light chain level is a weak risk factor for the development of MS.

artículo científico publicado en 2016

Oral laquinimod for multiple sclerosis: beyond the anti-inflammatory effect

artículo científico publicado en 2013

Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis.

artículo científico publicado en 2013

Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.

artículo científico publicado en 2009

Progression of regional grey matter atrophy in multiple sclerosis.

artículo científico publicado en 2018

Progressive MS trials: Lessons learned

artículo científico publicado en 2017

Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis.

artículo científico publicado en 2015

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

article

Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.

artículo científico publicado en 2016

Risk acceptance in multiple sclerosis patients on natalizumab treatment.

artículo científico publicado en 2013

Secondary progression is not the only explanation.

artículo científico publicado en 2014

Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder?

scientific article published on 10 September 2015

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

artículo científico publicado en 2015

Significant clinical worsening after natalizumab withdrawal: Predictive factors

article

Single-subject structural cortical networks in clinically isolated syndrome

artículo científico publicado en 2019

Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI

artículo científico publicado en 2012

Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.

artículo científico publicado en 2017

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor

artículo científico publicado en 2017

Structural cortical network reorganization associated with early conversion to multiple sclerosis

artículo científico publicado en 2018

Subcutaneous alemtuzumab for multiple sclerosis ⬇️

artículo científico publicado el 1 de julio de 2012

Understanding the role of gender and hormones in multiple sclerosis

Value of NMO-IgG determination at the time of presentation as CIS

artículo científico publicado en 2012

Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD

artículo científico publicado en 2018

Very early scans for demonstrating dissemination in time in multiple sclerosis

artículo científico publicado en 2008

Lista de obras de Carmen Tur

A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis

Acute disseminated encephalomyelitis: study of factors involved in a possible development towards multiple sclerosis

An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.

Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting

Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease.

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: No.

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

Clinical relevance of cortical network dynamics in early primary progressive MS

Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al

Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody

Commentary on Pique et al.'s paper entitled: Peripheral late reactivation of a previously typical monofocal Balo's concentric sclerosis lesion.

Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis

Deep grey matter volume loss drives disability worsening in multiple sclerosis.

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Disrupted principal network organisation in multiple sclerosis relates to disability

Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

Early accurate diagnosis crucial in multiple sclerosis

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

Erratum: Author Correction: High-dimensional detection of imaging response to treatment in multiple sclerosis

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

Fatigue Management in Multiple Sclerosis

Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis

Fármacos modificadores de la enfermedad en la esclerosis múltiple y embarazo

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis.

HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis

HLA-DRB1*15 influences the development of brain tissue damage in early PPMS

Has the time come to revisit our standard measures of disability progression in MS?

Head-to-head drug comparisons in multiple sclerosis: Urgent action needed

Hemichorea-hemiballism secondary to infarction in the primary motor area: an atypical form of presentation of Moya moya syndrome

High-dimensional detection of imaging response to treatment in multiple sclerosis

Ibudilast: a paradigm shift for progressive MS?

Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis

Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.

Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis.

Multiple sclerosis risk perception and acceptance for Brazilian patients

NMO spectrum disorders: how wide is the spectrum?

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision

Natalizumab: risk stratification of individual patients with multiple sclerosis

Neurite dispersion: a new marker of multiple sclerosis spinal cord pathology?

Neurofilament light chain level is a weak risk factor for the development of MS.

Oral laquinimod for multiple sclerosis: beyond the anti-inflammatory effect

Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis.

Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.

Progression of regional grey matter atrophy in multiple sclerosis.

Progressive MS trials: Lessons learned

Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis.

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.

Risk acceptance in multiple sclerosis patients on natalizumab treatment.

Secondary progression is not the only explanation.

Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder?

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

Significant clinical worsening after natalizumab withdrawal: Predictive factors

Single-subject structural cortical networks in clinically isolated syndrome

Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI

Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor

Structural cortical network reorganization associated with early conversion to multiple sclerosis

Subcutaneous alemtuzumab for multiple sclerosis ⬇️

Understanding the role of gender and hormones in multiple sclerosis

Value of NMO-IgG determination at the time of presentation as CIS

Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD

Very early scans for demonstrating dissemination in time in multiple sclerosis